Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2 results about "Hepatic parenchymal cell" patented technology

Quick Answer. Hepatic parenchymal disease is damage to the functional cells of the liver, according to HealthTap. Liver diseases can be divided into those affecting the biliary ducts and those affecting the functional cells of the organ, known as the parenchyma.

Preparation method and application of large-size human liver organoids

ActiveCN121852313BCell AggregationsHepatic parenchymal cell
The application discloses a preparation method and application of large-size human liver organoids, and belongs to the technical field of cell culture. In the application, 2D culture mature human primary liver parenchymal cells with different cell amounts are resuspended by using a hepatocyte maturation medium HIM, and are added into a U-shaped bottom 96-hole plate for low-oxygen static culture. After the cells are aggregated, the cells are cultured in normal oxygen and are shaken, so that large-size human liver organoids with different cell contents are prepared. The method does not need biological materials, and can induce human primary liver parenchymal cells to self-assemble and construct functional liver organoids with high uniformity in scale through specific culture conditions. The method solves the problems of large batch difference, high heterogeneity and dedifferentiation in the prior art, and can be widely applied to drug hepatotoxicity testing, in-vitro modeling of liver diseases and development of a bioartificial liver system.
Owner:INST OF BIOMEDICAL ENG CHINESE ACAD OF MEDICAL SCI

Use of catalpol and mesenchymal stem cells in the preparation of drugs for treating liver fibrosis

This invention belongs to the field of biomedical technology and discloses the use of catalpol and mesenchymal stem cells in the preparation of drugs for treating liver fibrosis, wherein the concentration of catalpol is 50–200 μM and the concentration of exosomes is 20–50 μg / mL. Simultaneously, this invention constructs a spatially resolved liver fibrosis chip model based on GelMA hydrogel, integrating Kupffer-like cells, hepatic stellate cells, hepatic parenchymal cells, and endothelial cells through a layered sequential seeding strategy, achieving high-precision biomimicry of the liver fibrosis microenvironment. In vitro chip and in vivo animal experiments confirmed that this combined approach can significantly inhibit the expression of collagen synthesis-related genes, improve liver function indicators, and effectively reduce collagen deposition; its anti-fibrotic efficacy is significantly better than the simple superposition of the effects of single components, exhibiting a clear synergistic effect. This invention provides a novel synergistic drug strategy and a highly biomimetic in vitro evaluation platform for the treatment of liver fibrosis.
Owner:DALIAN UNIV OF TECH